ArticleCancer science2018

Dose-finding study of the checkpoint kinase 1 inhibitor, prexasertib, in Japanese patients with advanced solid tumors.

Satoru Iwasa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.